Another "approvable" for Advair Diskus
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's Advair Diskus (fluticasone propionate/salmeterol inhalation powder) is "approvable" Dec. 12 for chronic obstructive pulmonary disease. A March 5 approvable letter requested more efficacy data and further safety data on long-term use in COP